We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI-Enhanced Platform Detects Cardiac Amyloidosis by Assessing Single Echocardiogram

By MedImaging International staff writers
Posted on 27 Apr 2023
Print article
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)

Cardiac amyloidosis, a condition resulting from abnormal protein deposits in heart tissue, is a diverse disease that can be challenging to diagnose, often necessitating specialized expertise and testing. The disease is categorized based on the specific protein involved, with the primary subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by the misfolding of the transthyretin protein, and a less common form called light chain amyloidosis (AL cardiac amyloidosis), caused by the buildup of immunoglobulin light chains. Now, an AI-powered platform can detect cardiac amyloidosis by analyzing echocardiograms and using just one commonly acquired ultrasound view of the heart.

The platform, EchoGo Amyloidosis, from Ultromics (Oxford, UK) utilizes AI technology to address the unmet need for early diagnosis of amyloidosis patients, who might otherwise remain undiagnosed until the disease has progressed, delaying treatment and negatively affecting patient outcomes. Developed in collaboration with multiple leading clinical partners, EchoGo Amyloidosis is designed as a module within Ultromics' EchoGo Platform and has received FDA Breakthrough Device Status. This FDA Breakthrough Device Designation represents a significant advancement for amyloidosis patients, who face a bleak five-year mortality rate of 44%-65% after diagnosis if the condition is not detected early enough.

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients."

Related Links:
Ultromics 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Under Table Shield
3 Section Double Pivot Under Table Shield
Portable Radiology System
DRAGON ELITE & CLASSIC
New
Brachytherapy Planning System
Oncentra Brachy

Print article
Radcal

Channels

MRI

view channel
Image: PET/MRI can accurately classify prostate cancer patients (Photo courtesy of 123RF)

PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients

The Prostate Imaging Reporting and Data System (PI-RADS) is a five-point scale to assess potential prostate cancer in MR images. PI-RADS category 3 which offers an unclear suggestion of clinically significant... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

General/Advanced Imaging

view channel
Image: The Tyche machine-learning model could help capture crucial information. (Photo courtesy of 123RF)

New AI Method Captures Uncertainty in Medical Images

In the field of biomedicine, segmentation is the process of annotating pixels from an important structure in medical images, such as organs or cells. Artificial Intelligence (AI) models are utilized to... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.